CLINICAL TRIAL OPPORTUNITIES

Ohio Gastroenterology Group, Inc. participates in pharmaceutical clinical research, offering patients opportunities to new cutting edge treatment.

Interested in Clinical Trials?

Current therapeutic areas being researched are:

Entyvio Dual Targeted Therapy with Xeljanz – Phase 4 Trial
For adults 18 to 65 with moderate to sever Ulcerative Colitis.(Other eligibility requirements must be met as well.)
Study drugs, study-related procedures and tests will be provided at no cost. $200.00 stipend provided at each completed research visit.

Drug RO7790121 or Placebo – Phase 3 Trial
For adults 18 to 80 years old with moderate to severe Ulcerative Colitis. (Other eligibility requirements must be met as well.)
Study drug will be provided at no cost. $175.00 to $550.00 patient stipend depending on the type of service provided at each completed research visit.
Dual Therapy with Entyvio plus Humira or Stelara
For adults 18 to 65 years old with moderate to severe Crohn’s Disease. (Other eligibility requirements must be met as well.)
Study drugs, study-related procedures, and tests will be provided at no cost. $200.00 stipend provided at each completed research visit.
A Study to develop future test for colorectal cancer detection
One time blood draw for adults 45 to 85 years old with recent colonoscopy with or without colorectal cancer. (Other eligibility requirements must be met as well.)
The blood draw will be provided at no cost. $125.00 pre-paid visa gift card.

Clinical trial coming soon! Email staylor@ohiogastro.com if interested.

Clinical trial coming soon! Email staylor@ohiogastro.com if interested.

Clinical trial coming soon! Email staylor@ohiogastro.com if interested.

Clinical trial coming soon! Email staylor@ohiogastro.com if interested.

Contact us today to see if you qualify for any of our current clinical trials.

staylor@ohiogastro.com

Why Participate in a Clinical Trial?

While trials vary, here are some potential benefits from participating:

  • Additional detailed care
  • Access to new treatments not available to the public
  • Contribution to the development of promising future drugs, prevention treatments, or medical devices that may help others